Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances
Series type: Risk assessments
Summary
This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at its 61st regular session, the Commission on Narcotic Drugs (CND) decided to place 5F-MDMB-PINACA in Schedule II of the Convention on Psychotropic Substances of 1971 based on a recommendation by the World Health Organization. This recommendation was substantially supported by European data provided by the EMCDDA.
Table of contents
- Foreword
- EMCDDA actions on monitoring and responding to new drugs
- Europol–EMCDDA Joint Report on 5F-MDMB-PINACA (methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate) — a summary
- Risk Assessment Report on a new psychoactive substance: methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA)
- Technical report on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA)
- Participants of the risk assessment meeting, 7-8 November 2017
Main subject:
Pages:
64
Price:
free
ISBN:
978-92-9497-314-6
ISSN:
1725-4493
Pub. DOI:
10.2810/868403
Catalog Number:
TD-AK-18-006-EN-N